Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 4/2010

01-04-2010 | Original Article

Outcome After Curative Resection of Large (≥10 cm) Gastric Gastrointestinal Stromal Tumors: How Frequent is Adjacent Organ Involvement and is Concomitant Distal Pancreatectomy Necessary?

Authors: Brian K. P. Goh, Pierce K. H. Chow, Sittampalam M. Kesavan, Wai-Ming Yap, Yaw-Fui A. Chung, Wai-Keong Wong

Published in: Journal of Gastrointestinal Surgery | Issue 4/2010

Login to get access

Abstract

Introduction

Complete tumor resection with clear margins including adjacent organs is the treatment of choice for gastrointestinal stromal tumors (GISTs). However, true tumor invasion of adjacent organs has been reported to be rare. Concomitant distal pancreatectomy (DP) for suspected tumor infiltration is not infrequently performed during resection of large gastric GISTs. This study aims to determine the true frequency of adjacent organ involvement by large gastric GISTs with particular attention to the pancreas and compares the outcome after curative resection with and without a concomitant DP in order to determine if DP is truly necessary.

Methods

A retrospective review of 37 patients who underwent curative resection of large (≥10 cm) gastric GISTs was conducted.

Results

Wedge resections were performed in 22, partial gastectomies in nine, and total gastrectomies in six patients. The median operative time was 180 min (range, 60–330 min), and the patients had a median postoperative stay of 8 days (range, 4–29 days). Overall, there were eight (22%) morbidities including two (5%) mortalities. Nineteen (51%) had concomitant adjacent organ resection, and these included 15 (41%) DPs with splenectomies. Direct organ invasion was demonstrated in 5/19 patients (26%) and 7/30 organs (23%) resected. Only 1/15 (6.7%) DP specimens demonstrated tumor infiltration. Comparison between the patients with and without a concomitant DP demonstrated that performance of a DP was associated with a longer operation time [225 min (range, 105–305 min) vs 158 min (60–330 min), P = .002)], increased postoperative stay [9 days (range, 7–29 days) vs 7.5 days (4–19 days), P = .042], and increased postoperative morbidity [6 (40%) vs 2 (9%), P = .025]. The DP cohort also had a statistically significant poorer 5-year recurrence free survival (22% vs 60%, P = .017).

Conclusion

Although adjacent organ involvement is not uncommon with large gastric GISTs, concomitant DP is usually unnecessary as direct pancreatic invasion is rare. Furthermore, concomitant DP with splenectomy is associated with an increase in postoperative morbidity.
Literature
1.
go back to reference Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumors. Br J Surg 2003;90:1178–1186.CrossRefPubMed Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumors. Br J Surg 2003;90:1178–1186.CrossRefPubMed
2.
go back to reference Winfield RD, Hochwald SN, Vogel SB, Hemming AW, Liu C, Cance WG, Grobmyer SR. Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg 2006;72:719–723.PubMed Winfield RD, Hochwald SN, Vogel SB, Hemming AW, Liu C, Cance WG, Grobmyer SR. Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg 2006;72:719–723.PubMed
3.
go back to reference Goh BK, Chow PK, Ong HS, Wong WK. Gastrointestinal stromal tumor involving the second and third portion of the duodenum: treatment by partial duodenectomy and Roux-en-Y duodenojejunostomy. J Surg Oncol 2005;91:273–275.CrossRefPubMed Goh BK, Chow PK, Ong HS, Wong WK. Gastrointestinal stromal tumor involving the second and third portion of the duodenum: treatment by partial duodenectomy and Roux-en-Y duodenojejunostomy. J Surg Oncol 2005;91:273–275.CrossRefPubMed
4.
go back to reference Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000;7:705–712.CrossRefPubMed Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000;7:705–712.CrossRefPubMed
5.
go back to reference Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–58.CrossRefPubMed Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–58.CrossRefPubMed
6.
go back to reference Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, Paul PG, Ooi BS, Chung YF, Wong WK. Which is the optimal risk stratification system for surgically treated localize primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal of a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol 2008;15:2153–2163.CrossRefPubMed Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, Paul PG, Ooi BS, Chung YF, Wong WK. Which is the optimal risk stratification system for surgically treated localize primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal of a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol 2008;15:2153–2163.CrossRefPubMed
7.
go back to reference Shiu MH, Farr GH, Papachristou DN, Hajdu SI. Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 1982;49:177–187.CrossRefPubMed Shiu MH, Farr GH, Papachristou DN, Hajdu SI. Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 1982;49:177–187.CrossRefPubMed
8.
go back to reference Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohistochemical and molecular genetic study of 1,765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52–68.CrossRefPubMed Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohistochemical and molecular genetic study of 1,765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52–68.CrossRefPubMed
9.
go back to reference Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003;6:39–48.CrossRefPubMed Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003;6:39–48.CrossRefPubMed
10.
go back to reference Goh BK, Tan YM, Chung YF, Cheow PC, Ong HS, Chan WH, Chow PK, Soo KC, Wong WK, Ooi LL. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome and management of the postoperative pancreatic fistula. A 21-year experience at a single institution. Arch Surg 2008;143:956–965.CrossRefPubMed Goh BK, Tan YM, Chung YF, Cheow PC, Ong HS, Chan WH, Chow PK, Soo KC, Wong WK, Ooi LL. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome and management of the postoperative pancreatic fistula. A 21-year experience at a single institution. Arch Surg 2008;143:956–965.CrossRefPubMed
11.
go back to reference Kleef J, Diener MK, Z’graggen K et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg 2007;245:573–582.CrossRef Kleef J, Diener MK, Z’graggen K et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg 2007;245:573–582.CrossRef
12.
go back to reference Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459–465.CrossRefPubMed Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459–465.CrossRefPubMed
13.
go back to reference Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8–13.CrossRefPubMed Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8–13.CrossRefPubMed
14.
go back to reference Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch Surg 2002;137:164–168.CrossRefPubMed Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch Surg 2002;137:164–168.CrossRefPubMed
15.
go back to reference Dematteo RP, Heinrich MC, El-Rifai WM et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466–477.CrossRefPubMed Dematteo RP, Heinrich MC, El-Rifai WM et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466–477.CrossRefPubMed
16.
go back to reference Hsu KH, Yang TM, Shan YS, Lin PW. Tumor size is a major determinant of recurrence in patients with respectable gastrointestinal stromal tumor. Am J Surg 2007;194:148–152.CrossRefPubMed Hsu KH, Yang TM, Shan YS, Lin PW. Tumor size is a major determinant of recurrence in patients with respectable gastrointestinal stromal tumor. Am J Surg 2007;194:148–152.CrossRefPubMed
17.
go back to reference Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006;32:961–963.CrossRefPubMed Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006;32:961–963.CrossRefPubMed
18.
go back to reference DeMatteo RP, Ballman KV, Antonescu C et al. Adjuvant imatinib mesylate after resection of localized primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009;373:1097–104.CrossRefPubMed DeMatteo RP, Ballman KV, Antonescu C et al. Adjuvant imatinib mesylate after resection of localized primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009;373:1097–104.CrossRefPubMed
19.
go back to reference Miettinen M, Makhlouf H, Sobin LH et al. Gastrointestinal stromal tumors of the stomach. Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466–1478.PubMed Miettinen M, Makhlouf H, Sobin LH et al. Gastrointestinal stromal tumors of the stomach. Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466–1478.PubMed
Metadata
Title
Outcome After Curative Resection of Large (≥10 cm) Gastric Gastrointestinal Stromal Tumors: How Frequent is Adjacent Organ Involvement and is Concomitant Distal Pancreatectomy Necessary?
Authors
Brian K. P. Goh
Pierce K. H. Chow
Sittampalam M. Kesavan
Wai-Ming Yap
Yaw-Fui A. Chung
Wai-Keong Wong
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 4/2010
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-009-1083-4

Other articles of this Issue 4/2010

Journal of Gastrointestinal Surgery 4/2010 Go to the issue